The company, which used gene sequencing to screen for disease-causing mutations, said the Series B preferred stock financing would be used to boost its commercial efforts and support further R&D.
Good Start has recently made a string of hires in its finance, HR and customer care departments, including taking on former Genzyme senior vice president Jean Franchi.
President and CEO Don Hardison said, “We are pleased to complete the initial closing of our second financing as it provides the necessary funding to position Good Start Genetics for the next phase of growth.
“We value the vote of confidence and continued support from our current stockholders and are fortunate to have such a supportive group of world-class investors on our side.”
Investment firm OrbiMed backs companies across the pharmaceutical, biotech and medical device sectors and has more than $5bn of assets under management.
It closed its latest fund Royal Opportunities on $600m last August.
Copyright © 2012 AltAssets